ANNUAL REPORT FY23 49 9. Issued capital 2023 2022 2023 2022 Shares Shares $ $ Ordinary shares - fully paid 156,008,700 156,008,700 25,320,332 25,320,332 Common stock 30 June 2023 30 June 2022 30 June 2023 30 June 2022 Shares Shares $ $ At the beginning of reporting period/year 156,008,700 156,008,700 25,320,332 25,320,332 The Company has CHESS Depositary Interests (CDIs) quoted on the Australian Securities Exchange (ASX) trading under the ASX code NYR. Each CDI represents an interest in one share of Class A common stock of the Company (Share). Legal title to the Shares underlying the CDIs is held by CHESS Depositary Nominees Pty Ltd (CDN), a wholly owned subsidiary of the ASX. The Company’s securities are not quoted on any other exchange. CDI Holders are entitled to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. CDI Holders may attend and vote at Nyrada’s general meetings. The Companymust allowCDI Holders to attend anymeeting of Shareholders unless relevant U.S. law at the time of the meeting prevents CDI Holders from attending those meetings. Performance Common Stock The Company has issued the following Performance Common Stock in the Company (Performance Shares): 2023 2022 No No At the beginning of the reporting period 18,000,000 18,000,000 The Performance Shares shall be convertible into 18,000,000 Shares upon the achievement of the milestones referred to below on or before 25 November 2024. The fair value of each Performance Share at grant date is $0.08: Holder Performance shares Performance milestones Noxopharm Limited 6,000,300 The later to occur of: • the trading price for the Company’s CDIs achieving at least AU$0.40 for 5 consecutive trading days on the ASX; and • the Scientific Advisory Board to the Company determining that, based on in-vivo data, the final lead neuroprotectant drug candidate is ready to proceed to pre-clinical safety and toxicology studies. 6,000,300 The later to occur of: • the trading price for the Company’s CDIs achieving at least AU$0.40 for 5 consecutive trading days on the ASX; and • the Scientific Advisory Board to the Company determining that, based on in-vivo data, the final lead peripheral neuropathic pain drug candidate is ready to proceed to pre-clinical safety and toxicology studies. Altnia Holdings Pty Ltd 5,999,400 The later to occur of: • the trading price for the Company’s CDIs achieving at least AU$0.40 for 5 consecutive trading days on the ASX; and • the Scientific Advisory Board to the Company determining that, based on in-vivo data, the final lead PCSK9 inhibiter drug candidate is ready to proceed to pre-clinical safety and toxicology studies. Total 18,000,000
RkJQdWJsaXNoZXIy MjE2NDg3